Precision medicine for non-small cell lung cancer (NSCLC)

With precision medicine becoming a more integral component of NSCLS treatment, molecular testing is an important step in helping researchers, pathologists, and oncologists understand the genetic underpinnings of this disease. Pathologists commonly use immunohistochemistry and next-generation sequencing to characterize lessons and refine diagnoses, while circulating tumour DNA analysis has emerged as a promising, non-invasive companion diagnostic.

This white paper explores the roles IHC, NGS and ctDNA play in NSCLC precision medicine therapy development, as well as how they help healthcare providers determine the most effective treatment regimens for their patients. Download to find out more.

COVID-19 Therapy Development and Clinical Diagnostics

While most people with COVID-19 recover within a few weeks, a notable percentage experience symptoms that last for 12 weeks or longer. With therapy development, we look into clinical diagnostics.

As scientists discover new variants, new questions become more relevant: How will variants impact vaccine efficacy? Who will need booster shots? Will we need new vaccines? Targeting a multifaceted disease such as COVID-19 requires a diverse team of infectious disease experts; it will also requires a central lab and clinical diagnostics partner with the expertise and portfolio of testing to serve sponsors’ varied needs.

As the effort to develop more effective COVID-19 treatments and vaccines and protect the global public continues, therapy and vaccine developers must partner with central labs that offer a broad scope of services. A diverse portfolio of exploratory tools and tests is paramount when studying an unpredictable virus.

Find out more about Cerba’s research into COVID-19 by downloading our white paper.

IVDR: How to Prepare for New Regulations and Move Successfully to CE Mark

The new Vitro Diagnostic Regulation legislation comes into force on May 26, 2022. Diagnostic device manufacturers are working hard to ensure design, manufacturing, and post-market surveillance and vigilance of their products comply with the new regulations. As the clock ticks, few manufacturers are fully prepared: according to a survey conducted by MedTech Summit and NSF in early 2021, only 15% of respondent organizations were fully prepared to meet the IVDR deadline. One of the main reasons for the delay was COVID-19. Almost all (95%) of respondents said the pandemic had impacted their IVDR implementation. While the European Commission recently proposed to adapt the full IVDR mandatory application dates depending on the class of medical device, organizations that are not already working with a Notified Body on CE mark submission may have a tough few years ahead. Download our whitepaper to find out more from Cerba Research.

White Paper: Flow Cytometry Advantages in Immunotherapy Clinical Trials

Our white paper takes an in-depth look at the world of flow cytometry. Nithianandan Selliah, Global Head of Flow Cytometry, and Ishita Modi, Director, Scientific Customer Solutions at Cerba Research, examine its unique benefits and future potential. They highlight the latest trends in technology and set out the key points to consider when planning a flow cytometry-based clinical trial and choosing a partner lab.

Nonnegotiable Central Laboratory Capabilities for I/O Clinical Trial Success

In immuno-oncology (I/O), meeting budget and timeline expectations in the journey from translational research to commercialization is a challenge. You need expert, integrated clinical laboratory and diagnostic solutions delivered by top scientists who will help you assess needs and generate early insights that optimize your protocol.

What else should you look for in a clinical laboratory partner? Along with access to a sizable patient database, impeccable performance across the globe, and I/O experience, three main testing capabilities are mandatory for success in this field: immunohistochemistry, flow cytometry, and next generation sequencing.

White Paper: Flow Cytometry Advantages in Immunotherapy Clinical Trials

Our white paper takes an in-depth look at the world of flow cytometry. Nithianandan Selliah, Global Head of Flow Cytometry, and Ishita Modi, Director, Scientific Customer Solutions at Cerba Research, examine its unique benefits and future potential. They highlight the latest trends in technology and set out the key points to consider when planning a flow cytometry-based clinical trial and choosing a partner lab.